Proactive Investors - Run By Investors For Investors

Rhythm Bioscience tackles bowel cancer with accessible diagnostic tool

Rhythm Biosciences Ltd (ASX:RHY) managing director & CEO Trevor Lockett speaks to Proactive Investors about the health company’s development of a diagnostic tool for detecting colorectal or bowel cancer.
ColoSTAT, Rhythm’s antibody-based blood test, was granted a biomarker patent within Europe earlier this year.
“Colorectal cancer is one of the major killers globally … it’s also remarkable that colorectal cancer is one of the most curable cancers if detected early,” Lockett says.
He continues, “ColoSTAT is a blood test for bowel cancer. It’s based on the detection of proteins that change in concentration in the blood, in the situation of cancer versus normal disease. It’s designed to be a cost-effective, highly clinically effective and accessible test that will be taken by many people.”
View full RHY profile View Profile

Rhythm Biosciences Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use